Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice

Recent studies have shown the potential of broadly neutralizing antibodies (bnAbs) for HIV-1 treatment. One of the candidate antibodies moving into clinical trials is the bnAb PGDM1400. Here, we studied the therapeutic potency and escape pathways of bnAb PGDM1400 during monovalent therapy in human i...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Velden, Yme U., Villaudy, Julien, Siteur - van Rijnstra, Esther, van der Linden, Cynthia A., Vink, Monique A., Schermer, Edith E., Weijer, Kees, Berkhout, Ben, Sanders, Rogier W., van Gils, Marit J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755169/
https://www.ncbi.nlm.nih.gov/pubmed/33218286
http://dx.doi.org/10.1080/19420862.2020.1845908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755169/
https://www.ncbi.nlm.nih.gov/pubmed/33218286
http://dx.doi.org/10.1080/19420862.2020.1845908

Ejemplares similares